Image and quantify osteoporosis, arthritis, cancer metastases, and other bone diseases, as well as normal bone growth and resorption, in vivo with IVISense Osteo 800 Fluorescent Probes. As opposed to other imaging modalities such as CT or x-ray which raise the risk of harmful irradiation to the subject, in vivo fluorescence imaging offers no radiation exposure concerns, and when performed with optimized hydroxyapatite-targeted probes such as OsteoSense, can image and quantify bone growth and elucidate the biology of bone remodeling.
OsteoSense is available in 3 wavelengths: 680, 750, and 800.
IVISense Osteo 800 NIR fluorescent bisphosphonate imaging agents are designed to bind with high affinity to hydroxyapatite (HA) both in vivo and in vitro. Since HA is known to bind pyrophosphonates and phosphonates as well as synthetic bisphosphonates with high affinity, OsteoSense agents offer a safe and easy means to assess the subtle bone mineral changes that occur in bone growth, bone loss, and in diseases that damage bone, using subtherapeutic doses for imaging. IVISense Osteo 800 Fluorescent Probe is excited by 780 ± 10 mn excitation light and emits at 805 ± 10 mn. Including Osteo 800 in careful experimental design allows for multiplexing with other channels and/or imaging times, and so can be paired with other probes to achieve maximum efficiency and flexibility in imaging.